QTORIN 3.9% Rapamycin Anhydrous Gel
Pachyonychia Congenita (PC)
Key Facts
About Palvella Therapeutics
Palvella Therapeutics is a public, clinical-stage biotech company with a mission to develop and commercialize novel therapies for rare genetic dermatological conditions with profound unmet medical need. Its core achievement is the development of the QTORIN™ drug delivery platform and its lead candidate, QTORIN rapamycin gel, which has reported positive Phase 3 data for the treatment of pachyonychia congenita (PC). The company's strategy is to leverage its proprietary formulation to achieve deep tissue penetration of rapamycin, targeting the root mTOR-driven pathology in specific keratin disorders, thereby pursuing rapid regulatory pathways and establishing a durable franchise in orphan dermatology.
View full company profileAbout Palvella Therapeutics
Palvella Therapeutics is a public, clinical-stage biotech company with a mission to develop and commercialize novel therapies for rare genetic dermatological conditions with profound unmet medical need. Its core achievement is the development of the QTORIN™ drug delivery platform and its lead candidate, QTORIN rapamycin gel, which has reported positive Phase 3 data for the treatment of pachyonychia congenita (PC). The company's strategy is to leverage its proprietary formulation to achieve deep tissue penetration of rapamycin, targeting the root mTOR-driven pathology in specific keratin disorders, thereby pursuing rapid regulatory pathways and establishing a durable franchise in orphan dermatology.
View full company profileAbout Palvella Therapeutics
Palvella Therapeutics is a public, clinical-stage biotech company with a mission to develop and commercialize novel therapies for rare genetic dermatological conditions with profound unmet medical need. Its core achievement is the development of the QTORIN™ drug delivery platform and its lead candidate, QTORIN rapamycin gel, which has reported positive Phase 3 data for the treatment of pachyonychia congenita (PC). The company's strategy is to leverage its proprietary formulation to achieve deep tissue penetration of rapamycin, targeting the root mTOR-driven pathology in specific keratin disorders, thereby pursuing rapid regulatory pathways and establishing a durable franchise in orphan dermatology.
View full company profileTherapeutic Areas
Other Pachyonychia Congenita (PC) Drugs
| Drug | Company | Phase |
|---|---|---|
| MTORX™ Platform | Biomendics | Preclinical |